Better business coming in than going out: management describes the quality of new intake visibly exceeding what it is re
The model's full reasoning — Q3 2022 call → NOWe need to determine if management conveys that the business being taken in now is of visibly higher quality than the business it is finishing/replacing, with both halves present: (1) an in-versus-out quality contrast stated by management, and (2) the turnover is real, current, and already in the numbers' future. Let's examine the transcript. The call is about Cue Biopharma, a biotech company. They discuss clinical trials, data, and pipeline. The concept of "business" here likely refers to the clinical programs, products, or perhaps partnerships. But the question is about incoming vs outgoing business quality. In biotech, this could be about new drug candidates vs old, or new indications vs old, or perhaps about the quality of the data from new trials vs old. However, the question specifically asks about "business the company is TAKING IN RIGHT NOW" vs "the business it is finishing, replacing, or letting run off". This could be about contracts, orders, customers, products, engagements. In a biotech context, it might be about the pipeline: new drug candidates (CUE-102) vs old (CUE-101)? Or perhaps about the quality of the patient population? But the question is about economic quality: better priced, better margined, better terms, longer duration, more valuable work, etc. Looking at the transcript, management talks about CUE-101 and CUE-102. They mention that CUE-102 shares 99% sequence identity with CUE-101, and that they were able to start at a higher dose due to derisking. They also talk about the platform being derisked. But is there a contrast between incoming and outgoing business? They talk about the data from CUE-101 monotherapy and combination, and they are excited about the potential. They also mention that they have treated first patient with CUE-102. But do they contrast the quality of the incoming business (e.g., CUE-102) against the outgoing (e.g., CUE-101)? Not really in terms of economics. They talk about the platform being derisked, which might imply that future candidates are cheaper to develop, but that's not about incoming vs outgoing business in the sense of orders or contracts. The question is about "business" as in revenue-generating activities. In biotech, revenue might come from partnerships, collaborations, or product sales. But here, they have collaboration revenue, but they don't discuss new contracts vs old.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| GIII | G-III Apparel Group, Ltd. | Q4 2024 | 2024-03-14 | C |
| ALL | The Allstate Corporation | Q3 2023 | 2023-11-02 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| BRX | Brixmor Property Group Inc. | Q1 2023 | 2023-05-02 | A |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| BBD | Banco Bradesco S.A. | Q3 2022 | 2022-11-09 | D |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| GECC | Great Elm Capital Corporation | Q3 2018 | 2018-11-13 | B |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| T | AT&T Inc. | Q3 2018 | 2018-10-24 | C+ |
| ESS | Essex Property Trust, Inc. | Q2 2018 | 2018-08-03 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| HSTM | HealthStream, Inc. | Q3 2017 | 2017-10-24 | C |
| MTG | MGIC Investment Corporation | Q3 2017 | 2017-10-18 | B+ |
| BLKB | Blackbaud, Inc. | Q1 2017 | 2017-05-02 | B+ |
HSTM · Q3 2017 → YESThe question is about whether management conveys that the business they're taking in right now is of visibly higher quality than the business they're finishing or letting run off. YES The transcript shows management explicitly contrasting incoming business against outgoing: - Patient Experience: "Existing clients also continue to convert from a phone modality to email and SMS text surveying modality... This conversion trend to continue... expected to have a positive impact... on patient experience margins." (lower price, higher margin shift already happening) - Provider Solutions: "the move from installed software sales to software as service sales... challenge revenue growth... but not profitability growth" and "backlog of unimplemented customers... significantly reduced" - Laerdal/HeartCode: "the new product we believe is right now based on contracts.
GFS · Q3 2021 → YESThe question is about whether management conveys that the business they're taking in right now is of visibly higher quality than the business they're finishing or letting run off. YES The transcript shows management explicitly contrasting the incoming business with the outgoing: compute revenue is declining "as expected" due to customers shifting to smaller nodes, while "newer high-margin customer designs" are ramping in 2H 2022 to offset it. They tie this directly to mix improvement from "d differentiated solutions become a larger portion" and "feature-rich" platforms (FDX, RF SOI, silicon photonics) growing while feature-rich CMOS is flat or down. LTAs signed now carry "pricing improvements" baked in for 2022+, with new agreements committing future capacity at those better terms.
CYBR · Q3 2021 → YESThe question is about whether management conveys that the new business they're taking in is of higher quality than the old business they're replacing, and that as the old rolls off, results will impro...YES Management explicitly contrasts the incoming subscription business (new logos, SaaS bookings, Privileged Cloud, EPM) as higher-quality than the outgoing perpetual license business it is replacing. They describe it as delivering “faster type of value,” “higher lifetime value over time,” and “more users and more products faster ,” while noting that the current revenue and profitability headwind from the mix shift is “obscuring the P&L” and that results will improve once the transition completes.